2025
Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.Peer-Reviewed Original ResearchConceptsOverall survival of patientsBCLC staging systemTransarterial chemoembolizationOverall survivalStaging systemHepatocellular carcinomaStaging systems of hepatocellular carcinomaHepatocellular carcinoma staging systemsRetrospective single center studyKaplan Meier survival analysisInternational Staging SystemSingle center studyLog-rank testTertiary care centerPredicting overall survivalMeier survival analysisConsecutive patientsPrognostic stratificationStudy endpointPrognostic accuracyCenter studyPrognostic powerStratify outcomesMultivariate analysisPatients
2020
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition
Ghanim B, Rosenmayr A, Stockhammer P, Vogl M, Celik A, Bas A, Kurul IC, Akyurek N, Varga A, Plönes T, Bankfalvi A, Hager T, Schuler M, Hackner K, Errhalt P, Scheed A, Seebacher G, Hegedus B, Stubenberger E, Aigner C. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition. Scientific Reports 2020, 10: 5784. PMID: 32238865, PMCID: PMC7113285, DOI: 10.1038/s41598-020-62813-2.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitionC-reactive proteinMalignant pleural effusionKi-67 indexPD-L1Overall survivalPleural effusionPrognostic powerPD-L1 tumor proportion scoreNegative PD-L1 statusPD-L1 positive tumorsLonger median OSMedian overall survivalPD-L1 expressionPD-L1 statusTumor proportion scoreFurther prospective validationVariety of malignanciesICI therapyMedian OSSignificant prognosticatorShorter OSIndependent prognosticatorPrognostic roleDismal prognosis
2018
Systematic identification of mutations and copy number alterations associated with cancer patient prognosis
Smith J, Sheltzer J. Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. ELife 2018, 7: e39217. PMID: 30526857, PMCID: PMC6289580, DOI: 10.7554/elife.39217.Peer-Reviewed Original ResearchConceptsPatient prognosisSuccessful treatment decisionsDriver genesIndependent patient cohortsRobust prognostic biomarkerCancer patient prognosisSignificant prognostic powerSpecific therapeutic vulnerabilitiesSpecific cancer typesPatient cohortWorse outcomesDeadly malignancyPatient riskClinical riskPrognostic biomarkerTreatment decisionsPrognostic powerMolecular alterationsTherapeutic vulnerabilitiesCopy number alterationsCancer typesFocal CNAsTotal aneuploidyGenomic profilesPrognosisMixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade
Metzger‐Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz‐Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist 2018, 24: e441-e449. PMID: 30518616, PMCID: PMC6656459, DOI: 10.1634/theoncologist.2018-0363.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaDisease-free survivalHistologic gradeLobular carcinomaPostmenopausal womenSystemic therapyBetter prognosisAromatase inhibitorsPrognostic powerDisease-free survival advantageEarly-stage breast cancerFavorable disease-free survivalCox proportional hazards modelAdjuvant aromatase inhibitorsBaseline clinicopathologic characteristicsDetailed clinical databaseHER2-negative diseaseRetrospective cohort studyImportant prognostic factorKaplan-Meier methodProportional hazards modelIntermediate histologic gradeDistinct disease subtypesCohort studyOverall prognosis
2015
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
Wang L, Gong Y, Chippada-Venkata U, Heck M, Retz M, Nawroth R, Galsky M, Tsao C, Schadt E, de Bono J, Olmos D, Zhu J, Oh W. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Medicine 2015, 13: 201. PMID: 26297150, PMCID: PMC4546313, DOI: 10.1186/s12916-015-0442-0.Peer-Reviewed Original ResearchConceptsFour-gene modelCRPC patientsProstate cancerClinical parametersBackgroundCastration-resistant prostate cancerCastration-resistant prostate cancerSurvival of CRPC patientsGene-expression-based prognostic modelsBiomarker modelProstate cancer lethalityImmune cell componentsGene modelsGenes associated with cancer progressionMRNA profilesIntegrative genomic analysisWorse survivalPrognostic improvementBiological processesClinical predictorsAssociated with wide variationsCancer lethalityMyeloid cellsIntegrative genomics approachPrognostic powerCRPC
2012
Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer
Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE, Zacksenhaus E. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 5832-5837. PMID: 22460789, PMCID: PMC3326451, DOI: 10.1073/pnas.1201105109.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCalcium-Binding ProteinsCD24 AntigenCell DifferentiationCell DivisionEstrogen Receptor alphaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, NeoplasmHumansIntercellular Signaling Peptides and ProteinsJagged-1 ProteinMembrane ProteinsMiceNeoadjuvant TherapyNeoplastic Stem CellsPrognosisReceptor, ErbB-2Serrate-Jagged ProteinsSignal TransductionTrastuzumabTreatment OutcomeConceptsTumor-initiating cellsMammary tumor-initiating cellsBreast cancerClinical outcomesPrognostic signatureHuman epidermal growth factor receptorAnti-HER2 drugsAnti-HER2 therapyHigh-risk patientsHigh-risk subgroupsEpidermal growth factor receptorGrowth factor receptorBC cohortRisk patientsAggressive diseaseBC patientsRetrospective analysisImmune responsePrognostic powerTumor growthPatientsChemotherapyFactor receptorCancerFraction of cells
2007
Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test
Dewey FE, Freeman JV, Engel G, Oviedo R, Abrol N, Ahmed N, Myers J, Froelicher VF. Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test. American Heart Journal 2007, 153: 281-288. PMID: 17239690, DOI: 10.1016/j.ahj.2006.11.001.Peer-Reviewed Original ResearchConceptsHeart rate variabilitySquare successive differenceCardiovascular mortalityPrognostic powerHF powerExercise treadmill testingRoot mean square successive differenceFrequency-domain HRV analysisExercise stress testingExercise treadmill testMortality end pointsSuccessive differencesStandard exercise testingHeart rate variability responsesMinutes of recoveryStrongest predictorLow-frequency powerMean square successive differenceHigh-frequency powerR interval dataCardiovascular deathCause mortalityPeak exerciseClinical factorsExercise testing
2004
Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization
Liao L, Cabell CH, Jollis JG, Velazquez EJ, Smith WT, Anstrom KJ, Pappas PA, Ryan T, Kisslo JA, Landolfo CK. Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization. The American Journal Of Cardiology 2004, 93: 1275-1279. PMID: 15135703, DOI: 10.1016/j.amjcard.2004.01.071.Peer-Reviewed Original ResearchConceptsSevere left ventricular dysfunctionLeft ventricular dysfunctionVentricular dysfunctionDobutamine stress echocardiographySignificant survival advantageLong-term survivalCoronary diseaseStress echocardiographyViable myocardiumMyocardial viabilityPrognostic powerSurvival advantagePatientsRevascularizationDysfunctionEchocardiographyIschemiaMyocardiumDiseaseMonths
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply